Sign in →

Test ID: HBGCD Hepatitis B Surface Antigen for Cadaveric or Hemolyzed Specimens, Serum

Reporting Name

HBsAg Cadaver/Hemolyzed, S

Useful For

Testing cadaveric and hemolyzed blood specimens for hepatitis B surface antigen (HBsAg); US Food and Drug Administration-licensed for use with hemolyzed specimens


Diagnosis of acute, recent (<6-month duration), or chronic hepatitis B infection; determination of chronic hepatitis B carrier status


This test is not useful during the "window period" of acute hepatitis B virus (HBV) infection, (ie, after disappearance of HBsAg and prior to appearance of anti-HBs antibody).

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
BNTCD HBsAg Confirm Cadav/Hemol, S No No

Testing Algorithm

All reactive results are confirmed by a neutralization procedure at an additional charge.

Specimen Type


Additional Testing Requirements

Testing for acute hepatitis B virus (HBV) infection should also include HBIM / Hepatitis B Core Antibody, IgM, Serum as during the acute HBV infection "window period," HB surface (HBs) antigen and HBs antibody may not be detected.

Necessary Information

Date of collection is required.

Specimen Required

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Collection instructions:

1. Centrifuge blood collection tube per collection tube manufacturer's instructions (eg, centrifuge within 2 hours of collection for BD Vacutainer tubes).

2. Aliquot serum into plastic vial.

Specimen Minimum Volume

1.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Frozen (preferred) 30 days
  Ambient  7 days
  Refrigerated  7 days

Reference Values


Day(s) Performed

Monday, Thursday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information


87341 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HBGCD HBsAg Cadaver/Hemolyzed, S In Process


Result ID Test Result Name Result LOINC Value
83626 HBsAg Cadaver/Hemolyzed, S 5196-1

Clinical Information

Hepatitis B virus (HBV) is endemic throughout the world. The infection is spread primarily through percutaneous contact with infected blood products (eg, blood transfusion, sharing of needles by intravenous drug users). The virus is found in various human body fluids, and it is known to be spread through oral and genital contact. HBV can be transmitted from mother to child during delivery through contact with blood and vaginal secretions; it is not commonly transmitted transplacentally.


Hepatitis B surface antigen (HBsAg) is the first serologic marker appearing in the serum at 6 to 16 weeks following HBV infection. In acute infection, HBsAg usually disappears in 1 to 2 months after the onset of symptoms. Persistence of HBsAg for greater than 6 months indicates development of either a chronic carrier or chronic HBV infection.


A positive result (reactive screening and confirmed positive by neutralization test) is indicative of acute or chronic hepatitis B virus (HBV) infection or chronic HBV carrier state.


A positive confirmatory test result is considered the definitive test result for hepatitis B surface antigen (HBsAg). Specimens that are reactive by the screening test but negative (not confirmed) by the confirmatory test are likely to contain cross-reactive antibodies from other infectious or immunologic disorders. These unconfirmed HBsAg screening test results should be interpreted in conjunction with test results of other HBV serological markers (eg, anti-hepatitis B surface antibody, anti-hepatitis B core total antibody).


The presence of HBsAg is frequently associated with HBV infectivity, especially when accompanied by the presence of HBeAg or HBV DNA.

Clinical Reference

1. Servoss JC, Friedman LS: Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis. 2004 May;8(2):267-281

2. Badur S, Akgun A: Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol. 2001 Jun;21(3):229-237

3. Bonino F, Piratvisuth T, Brunetto MR, Liaw YF: Diagnostic markers of chronic hepatitis B infection and disease. Antivir Ther. 2010;15 Suppl 3:35-44

4. Terrault NA, Bzowej NH, Chang KM, et al: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261-283

Report Available

1 to 7 days

Method Name

Enzyme Immunoassay (EIA)


If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Client Test Request (T728) with the specimen.

Mayo Clinic Laboratories | Microbiology and Infectious Disease Catalog Additional Information: